Heart Failure, Microvascular Angina, Non-ischemic Cardiomyopathy
Conditions
Keywords
coronary microvascular dysfunction, non-ischemic cardiomyopathy
Brief summary
This study aims to evaluate the incidence of coronary microvascular dysfunction (CMD) and its prognostic implication for the improvement of left ventricular function in patients who have been diagnosed with heart failure with reduced ejection fraction (HFrEF) caused by non-ischemic etiology.
Detailed description
HF is a clinical syndrome characterized by dyspnea or exertional limitation due to impairment of ventricular filling or ejection of blood or both. HFrEF occurs when the left ventricular ejection fraction (LVEF) is 40% or less and is accompanied by progressive left ventricular dilatation and adverse cardiac remodeling. Among them, a substantial portion of patients had non-ischemic etiology.4 The CMD, defined by impaired coronary flow reserve (CFR), is commonly observed in patients with cardiomyopathies caused by non-ischemic etiology and is well-known to be associated with poor prognosis independently of the degree of left ventricular functional abnormality. However, the presence of CMD can be more specifically evaluated by invasive physiologic assessment using both CFR and the index of microcirculatory resistance (IMR) than by non-invasive methods (doppler echocardiography, positron emission tomography, or cardiac magnetic resonance imaging \[MRI\]) measuring CFR alone. Considering that CMD, defined by depressed CFR with elevated IMR, reflects the impaired myocardial flow and microvascular damages, there was a possibility that it may be a predictor of irreversible myocardial damages in HFrEF patients with non-ischemic etiology. Nevertheless, there has been limited data regarding the association between the improvement of LV function and CMD for patients with HFrEF caused by non-ischemic etiology after guideline-directed medical treatment (GDMT). Therefore, the investigators sought to evaluate the incidence of CMD and its prognostic implication for the improvement of left ventricular function after GDMT in patients who have been diagnosed with HFrEF caused by non-ischemic etiology.
Interventions
DIAGNOSTIC_TESTCMD test
Measured CFR and IMR
Sponsors
Samsung Medical Center
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* a) Subject must be at least 19 years of age. b) Subject with symptoms or signs of HF (NYHA ≥2 dyspnea) and reduced ejection fraction (LVEF ≤ 40%) c) Subject who clinically need coronary angiography d) Subject who can voluntarily sign informed consent form
Exclusion criteria
* a) Subject with significant coronary artery stenosis on coronary angiography (diameter stenosis ≥90% or 50-90% with fractional flow reserve \[FFR\] ≤0.80) b) Subject scheduled for cardiac replacement therapy (heart transplantation or left ventricular assisted device \[LVAD\] implantation) c) HF due to restrictive cardiomyopathy, active myocarditis, or constrictive pericarditis d) Significant valvular heart disease requiring surgery e) Subject who have non-cardiac co-morbid conditions with life expectancy \<1 year
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of HFiEF* at 12 months | 1-year follow-up | HFiEF was defined as LVEF \>40% measured by echocardiography at 12 months.1 |
Secondary
| Measure | Time frame |
|---|---|
| Correlation between CMD and delta LVEF from baseline to 12 months | 1 year |
| Correlation between CMD and E/e' | 1 year |
| Correlation between CMD and delta LV systolic dimension from baseline to 12 months | 1 year |
| Correlation between CMD and delta LV diastolic dimension from baseline to 12 months | 1-year follow-up |
| Correlation between CMD and late gadolinium enhancement measured by cardiac MRI | 1 year |
| Correlation between CMD and pulmonary artery wedge pressure | 1 year |
| Correlation between CMD and mean pulmonary artery pressure | 1 year |
| Correlation between CMD and pulmonary artery pulsatility index (PAPi) | 1 year |
| Correlation between CMD and cardiac output/cardiac index | 1 year |
| Correlation between CMD and left ventricular end diastolic pressure | 1 year |
| Proportion of CMD according to etiology | 1 year |
| Rates of All-cause death | 1-year follow-up |
| Rates of Cardiac death | 1-year follow-up |
| Rates of Readmission due to HF | 1-year follow-up |
| Rates of Readmission | 1-year follow-up |
| Rates of Implantation of implantable cardioverter defibrillator | 1-year follow-up |
| Rates of Cardiac replacement therapy (heart transplantation or LVAD) | 1-year follow-up |
| Changes of quality of life for HF (Kansas City Cardiomyopathy Questionnaire [KCCQ]) | 1-year follow-up |
| Total medical cost | 1-year follow-up |
| Correlation between CMD and delta NT-proBNP from baseline to 12 months follow-up | 1-year follow-up |
Countries
South Korea
Contacts
Primary ContactKi Hong Choi, MD
Outcome results
None listed